Regencell Bioscience Holdings Limited

NasdaqCM:RGC

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

🏥 Hospitals & Clinics

💊 Pharmaceuticals

💻 Telehealth

Location

Hong Kong

Market Cap

USD 10.05 B

Share Price

USD 17.40

Avg Daily Volume

700,338

Change (1 day)

-13.82%

Change (1 year)

394.32%

Change (YTD)

252.23%

Regencell Bioscience Holdings Limited Revenue for the year ending June 30, 2024: USD 0.00

Regencell Bioscience Holdings Limited Revenue is USD 0.00 for the year ending June 30, 2024. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Regencell Bioscience Holdings Limited Revenue for the year ending June 30, 2023 was USD 0.00.
Regencell Bioscience Holdings Limited Revenue for the year ending June 30, 2022 was USD 0.00.
Regencell Bioscience Holdings Limited Revenue for the year ending June 30, 2021 was USD 0.00.
Regencell Bioscience Holdings Limited Revenue for the year ending June 30, 2020 was USD 0.00.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

NasdaqCM: RGC

Regencell Bioscience Holdings Limited

CEO	Mr. Yat-Gai Au
IPO Date	July 16, 2021
Location	Hong Kong
Headquarters	First Commercial Building
Employees	12
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 🏥 Hospitals & Clinics 💊 Pharmaceuticals 💻 Telehealth

Description

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.